Recent Quotes (30 days)

You have no recent quotes
chg | %

Quest PharmaTech Inc  

(Public, CVE:QPT)   Watch this stock  
Find more results for QPT
0.0000 (0.00%)
Jun 29 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.05 - 0.05
52 week 0.03 - 0.11
Open 0.05
Vol / Avg. 6,520.00/22,804.00
Mkt cap 7.52M
P/E     -
Div/yield     -
EPS -0.04
Shares 150.42M
Beta 1.00
Inst. own     -

Key stats and ratios

Q1 (Jan '16) 2016
Net profit margin - -2055.46%
Operating margin - -857.91%
EBITD margin - -844.11%
Return on average assets -226.49% -84.61%
Return on average equity - -
CDP Score - -


8123 Roper Rd NW
+1-780-4481400 (Phone)
+1-780-4160324 (Fax)

Website links


Quest Pharmatech Inc (Quest) is a Canada-based biotechnology company. Quest is engaged in the development of the monoclonal antibody, Oregovomab (MAb B43.13), for the treatment of ovarian cancer. Quest's pipeline of product candidates consists of four monoclonal antibodies targeting certain tumor antigens that are presented in a range of cancers, including such cancers as breast, lung, pancreas, stomach and prostate. Quest has antibodies against MUC1, PSA, CA19.9 and TAG72. The Company's products, SL017, a topical formulation indicated for dermatology applications, and SL052, an injectable formulation, are developed using the SonoLight Technology. Quest has a supply and distribution agreement with Smart Cell Tec for the marketing and distribution rights for the anti-wrinkle skin care product, Bellus Skin. Quest is engaged in conducting two Phase II trials for its Oregovomab product for advanced ovarian cancer and for CA125 associated partially resectable pancreatic cancer.

Officers and directors

Lorne Meikle Independent Chairman of the Board
Ragupathy Madiyalakan Ph.D. Chief Executive Officer, Director
Pierre Vermette Chief Financial Officer
Thomas Woo Vice President - Product Development
Shawn Shuguang Lu Director
Ian McConnan Independent Director
Eric Shi MD, PhD Independent Director